Displaying 21 - 30 of 84 for Cancer - All
  • Cisplatin vs Paclitaxel for Triple Negative Breast Cancer (H-34421)
    • This research study is evaluating how well triple negative breast cancer responds to preoperative treatment with Cisplatin or Paclitaxel chemotherapy, and if use of a research test can predict response to preoperative treatment.
  • CITADEL Study (H-33900)
    • The purpose of this study is to investigate the efficacy of autologous EBV-specific T-cells for the treatment of patients with aggressive EBV positive extranodal NK/T-cell lymphoma.
  • CIVIC Study (H-39297)
    • The purpose of this study is to investigate the efficacy of autologous Epstein-Barr virus (EBV)-specific T cells for the treatment of EBV positive diffuse large B cell lymphoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disease.
  • COXEN Study (H-35336)
    • The primary focus of this study is to see if looking at tumor biomarkers using a program called coexpression extrapolation or "COXEN" may predict a patient's response to chemotherapy before surgery.
  • CRIZENT Study (H-33624)
    • CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer - In this study the investigators will be combining both of these two treatments, but at different doses.
  • Esophageal Cancer Study (H-34973)
    • The purpose of this study is to determine whether the use of a low-cost, high-resolution microendoscope during diagnostic upper endoscopy can improve the efficiency and accuracy of endoscopic screening for esophageal squamous cell neoplasia.
  • GARNET: Advanced Solid Tumors (H-40511)
    • This is a multicenter, open-label, first-in-human Phase 1 study evaluating the anti programmed death receptor 1 (anti-PD-1) antibody TSR-042 in patients with advanced solid tumors who have limited available treatment options.
  • Glioblastoma (iCAR) Study (H-31973)
    • The purpose of this study is to find the largest safe dose of HER2-CAR T cells, to learn what the side effects are, and to see whether this experimental intervention might help patients with glioblastoma.
  • Glioblastoma Multiforme Study (H-37782)
    • This randomized phase II/III trial studies how well temozolomide and veliparib work compared to temozolomide alone in treating patients with newly diagnosed glioblastoma multiforme.
  • GRALE Study (H-29617)
    • The purpose of this study is to find the largest safe dose of LMP-specific cytotoxic GRALE T cells created using this new manufacturing technique.